Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Asahi Kasei Corporation
Acquired Company
AiCuris Anti-infective Cures AG
Tokyo
WuppertalBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsDescription
Asahi Kasei has acquired AiCuris Anti-Infective Cures for €780 million, strengthening its position in severe infectious diseases. The acquisition includes the FDA-approved oral antiviral drug Hovilpri for treating herpes lesions in adults. This marks a significant advancement in treatment options for immunocompromised patients. The deal enhances Asahi Kasei's portfolio and expands its business in the healthcare sector.
Fundz sees it the moment Asahi Kasei Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired AiCuris Anti-infective Cures AG?
AiCuris Anti-infective Cures AG was acquired by Asahi Kasei Corporation, based in Tokyo. The deal was reported on October 12, 2026. Asahi Kasei Corporation is a multinational Japanese company offering a diversified range of products and providing services across various sectors including chemicals, homes, and health care. Asahi Kasei Corporation is privately held and operates in Biotechnology.
When did Asahi Kasei Corporation acquire AiCuris Anti-infective Cures AG?
Asahi Kasei Corporation's acquisition of AiCuris Anti-infective Cures AG was reported on October 12, 2026. Asahi Kasei has acquired AiCuris Anti-Infective Cures for €780 million, strengthening its position in severe infectious diseases. The acquisition includes the FDA-approved oral antiviral drug Hovilpri for treating herpes lesions in adults. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AiCuris Anti-infective Cures AG do?
AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. It is privately held, operating in Biotechnology, and is based in Wuppertal.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.